# Fiscal Year 2010 Annual Review of Amitiza®

# Oklahoma Health Care Authority April 2011

#### **Current Prior Authorization of Amitiza®**


- 1. Chronic Idiopathic Constipation in males and females 18 years of age and older who meet the following criteria, or IBS-Constipation predominant in females 18 years of age or older:
  - a. Have documentation that constipation-causing therapies for other disease states have been discontinued (excluding opioid pain medications for cancer patients).
  - b. Documented and updated Colon Screening (if >50 years of age).
- 2. Hydration and treatment attempts with a minimum of three alternate products must be documented.
- 3. Initial approval for 12 weeks of therapy. An additional year approval may be granted if physician documents member is responding well to treatment.
- 4. Quantity limit of 100 units for a 50 day supply applies.

#### **Utilization of Amitiza®**


# **Comparison of Fiscal Year Utilization**

Fiscal Year	Members	Claims	Paid	Paid/Claim	Perdiem	Units	Days
2009	67	221	\$42,411.15	\$191.91	\$6.44	12,307	6,590
2010	63	227	\$46,963.76	\$206.89	\$6.87	13,010	6,835
% Change	-6.00%	2.70%	10.70%	7.80%	6.70%	5.70%	3.70%
Change	-4	6	\$4,552.61	\$14.98	\$0.43	703	245

### Demographics of Members Utilizing Amitiza®: FY 2010








### Prior Authorization of Amitiza® Products

There were a total of 288 petitions submitted for this PBPA category during fiscal year 2010. The following shows the status of the submitted petitions.

Status of Petitions for Amitiza®: FY 2010



### **Conclusion and Recommendations**

The College of Pharmacy recommends no changes to this category at this time.

Medication	Claims	Units	Days	Members	Paid	Units/	Claims/	Per-
IVIEUICACIOII						Day	Member	diem
AMITIZA CAP 24MCG	199	11,078	5,870	48	\$39,438.82	1.89	4.15	\$6.72
AMITIZA CAP 8MCG	26	1,540	785	16	\$5,322.09	1.96	1.63	\$6.78
Totals	225	12,618	6,655	63*	\$44,760.91	1.9	3.52	\$6.73

<sup>\*</sup>Total Number of Unduplicated Members